Global Oligonucleiotide Synthesis Market

Oligonucleiotide Synthesis Comprehensive Study by Type (Custom Oligonucleotides, Pre-designed Oligonucleotides), Application (Research, Diagnostics, Therapeutics), End User (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, Hospitals), Products made from Oligonucleiotide (Oligonucleotide-based Drugs, Primers, Probes, Large-scale Synthesized Oligonucleotides, Intermediate-scale Synthesized Oligonucleotides, Linkers & Adaptors) Players and Region - Global Market Outlook to 2027

Oligonucleiotide Synthesis Market by XX Submarkets | Forecast Years 2022-2027 | CAGR: 13.9%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Oligonucleiotide Synthesis?
Oligonucleotide synthesis is referred to as the chemical synthesis of proportionally short fragments of the nucleic acids with stated chemical structure. The technique is especially useful in the practice of the current laboratory, as it provides rapid and inexpensive access to the custom-made oligonucleotides of the sequence as desired. Oligonucleotide synthesis is basically an integral part of the several ongoing genetic research studies. Growing investments in genetic research are anticipated for boosting demand for a custom synthesis of various classes of oligos which includes aptamers, decoys, immunostimulatory, antisense, miRNA and siRNA.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Billion)
Key Companies ProfiledAgilent Technologies, Inc., ATDBio Ltd. (United Kingdom), GE Healthcare, Eurofins Genomics (Germany), Eurogentec (Belgium), Bio-Synthesis, Inc., BioAutomation Corporation (United States), LGC Biosearch Technologies (United States), Biogen International (United States) and Thermo Fisher Scientific, Inc. (United States)
CAGR13.9%


The Global Oligonucleiotide Synthesis market is expected to see growth rate of 13.9% and may see market size of USD8.4 Billion by 2027. The study covers a detailed analysis segmented by key business segments i.e. by type (Custom Oligonucleotides and Pre-designed Oligonucleotides) , by application (Research, Diagnostics and Therapeutics) and major geographies. Research Analyst at AMA predicts that United States Vendors will contribute to the maximum growth of Global Oligonucleiotide Synthesis market throughout the predicted period.

The competition is expected to become even more intense in the years to come due to entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Oligonucleiotide Synthesis market analysis report suggests strategies Vendors can follow and recommends key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Vendors, some of them are Agilent Technologies, Inc., ATDBio Ltd. (United Kingdom), GE Healthcare, Eurofins Genomics (Germany), Eurogentec (Belgium), Bio-Synthesis, Inc., BioAutomation Corporation (United States), LGC Biosearch Technologies (United States), Biogen International (United States) and Thermo Fisher Scientific, Inc. (United States).

Market Overview:
In March 2018, Danaher acquired IDT, which enhanced Danaher’s Life Sciences platform and expanded its customer base.

Market Trend
Rise in Venture Capital Investments
Restraints
  • Price Erosion of Synthesized Oligos
  • Lack of A Unified Set of Regulations for therapeutic Oligos

Opportunities
Emerging Asian Markets

Key highlights of the Global Oligonucleiotide Synthesis market Study:
• CAGR of the market during the forecast period 2021-2027
• In-depth information on growth factors that will accelerate the Oligonucleiotide Synthesis market in next few years.
• Detailed Insights on futuristic trends and changing consumer behaviour
• Forecast of the Global Oligonucleiotide Synthesis market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Vendors
• Comprehensive information about factors that will challenge the growth of Oligonucleiotide Synthesis Vendors

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Oligonucleiotide Synthesis market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Oligonucleiotide Synthesis market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment>.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Custom Oligonucleotides
  • Pre-designed Oligonucleotides
By Application
  • Research
  • Diagnostics
  • Therapeutics
By End User
  • Academic & Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Diagnostic Laboratories
  • Hospitals

By Products made from Oligonucleiotide
  • Oligonucleotide-based Drugs
  • Primers
  • Probes
  • Large-scale Synthesized Oligonucleotides
  • Intermediate-scale Synthesized Oligonucleotides
  • Linkers & Adaptors

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Use of Synthesized Oligos in Molecular Diagnostics and Clinical Applications
      • 3.2.2. Increasing Government Investments and R&D Expenditure in Pharmaceutical and Biotechnology Companies
    • 3.3. Market Challenges
      • 3.3.1. Large-Scale Synthesis of Oligos
      • 3.3.2. Delivery of Oligonucleotide Drugs to Specific Targets
    • 3.4. Market Trends
      • 3.4.1. Rise in Venture Capital Investments
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Oligonucleiotide Synthesis, by Type, Application, End User, Products made from Oligonucleiotide and Region (value) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Oligonucleiotide Synthesis (Value)
      • 5.2.1. Global Oligonucleiotide Synthesis by: Type (Value)
        • 5.2.1.1. Custom Oligonucleotides
        • 5.2.1.2. Pre-designed Oligonucleotides
      • 5.2.2. Global Oligonucleiotide Synthesis by: Application (Value)
        • 5.2.2.1. Research
        • 5.2.2.2. Diagnostics
        • 5.2.2.3. Therapeutics
      • 5.2.3. Global Oligonucleiotide Synthesis by: End User (Value)
        • 5.2.3.1. Academic & Research Institutes
        • 5.2.3.2. Pharmaceutical & Biotechnology Companies
        • 5.2.3.3. Diagnostic Laboratories
        • 5.2.3.4. Hospitals
      • 5.2.4. Global Oligonucleiotide Synthesis by: Products made from Oligonucleiotide (Value)
        • 5.2.4.1. Oligonucleotide-based Drugs
        • 5.2.4.2. Primers
        • 5.2.4.3. Probes
        • 5.2.4.4. Large-scale Synthesized Oligonucleotides
        • 5.2.4.5. Intermediate-scale Synthesized Oligonucleotides
        • 5.2.4.6. Linkers & Adaptors
      • 5.2.5. Global Oligonucleiotide Synthesis Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Oligonucleiotide Synthesis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Agilent Technologies, Inc.
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. ATDBio Ltd. (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GE Healthcare
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eurofins Genomics (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eurogentec (Belgium)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bio-Synthesis, Inc.
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. BioAutomation Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. LGC Biosearch Technologies (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Biogen International (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Thermo Fisher Scientific, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Oligonucleiotide Synthesis Sale, by Type, Application, End User, Products made from Oligonucleiotide and Region (value) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Oligonucleiotide Synthesis (Value)
      • 7.2.1. Global Oligonucleiotide Synthesis by: Type (Value)
        • 7.2.1.1. Custom Oligonucleotides
        • 7.2.1.2. Pre-designed Oligonucleotides
      • 7.2.2. Global Oligonucleiotide Synthesis by: Application (Value)
        • 7.2.2.1. Research
        • 7.2.2.2. Diagnostics
        • 7.2.2.3. Therapeutics
      • 7.2.3. Global Oligonucleiotide Synthesis by: End User (Value)
        • 7.2.3.1. Academic & Research Institutes
        • 7.2.3.2. Pharmaceutical & Biotechnology Companies
        • 7.2.3.3. Diagnostic Laboratories
        • 7.2.3.4. Hospitals
      • 7.2.4. Global Oligonucleiotide Synthesis by: Products made from Oligonucleiotide (Value)
        • 7.2.4.1. Oligonucleotide-based Drugs
        • 7.2.4.2. Primers
        • 7.2.4.3. Probes
        • 7.2.4.4. Large-scale Synthesized Oligonucleotides
        • 7.2.4.5. Intermediate-scale Synthesized Oligonucleotides
        • 7.2.4.6. Linkers & Adaptors
      • 7.2.5. Global Oligonucleiotide Synthesis Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Oligonucleiotide Synthesis: by Type(USD Billion)
  • Table 2. Oligonucleiotide Synthesis Custom Oligonucleotides , by Region USD Billion (2016-2021)
  • Table 3. Oligonucleiotide Synthesis Pre-designed Oligonucleotides , by Region USD Billion (2016-2021)
  • Table 4. Oligonucleiotide Synthesis: by Application(USD Billion)
  • Table 5. Oligonucleiotide Synthesis Research , by Region USD Billion (2016-2021)
  • Table 6. Oligonucleiotide Synthesis Diagnostics , by Region USD Billion (2016-2021)
  • Table 7. Oligonucleiotide Synthesis Therapeutics , by Region USD Billion (2016-2021)
  • Table 8. Oligonucleiotide Synthesis: by End User(USD Billion)
  • Table 9. Oligonucleiotide Synthesis Academic & Research Institutes , by Region USD Billion (2016-2021)
  • Table 10. Oligonucleiotide Synthesis Pharmaceutical & Biotechnology Companies , by Region USD Billion (2016-2021)
  • Table 11. Oligonucleiotide Synthesis Diagnostic Laboratories , by Region USD Billion (2016-2021)
  • Table 12. Oligonucleiotide Synthesis Hospitals , by Region USD Billion (2016-2021)
  • Table 13. Oligonucleiotide Synthesis: by Products made from Oligonucleiotide(USD Billion)
  • Table 14. Oligonucleiotide Synthesis Oligonucleotide-based Drugs , by Region USD Billion (2016-2021)
  • Table 15. Oligonucleiotide Synthesis Primers , by Region USD Billion (2016-2021)
  • Table 16. Oligonucleiotide Synthesis Probes , by Region USD Billion (2016-2021)
  • Table 17. Oligonucleiotide Synthesis Large-scale Synthesized Oligonucleotides , by Region USD Billion (2016-2021)
  • Table 18. Oligonucleiotide Synthesis Intermediate-scale Synthesized Oligonucleotides , by Region USD Billion (2016-2021)
  • Table 19. Oligonucleiotide Synthesis Linkers & Adaptors , by Region USD Billion (2016-2021)
  • Table 20. South America Oligonucleiotide Synthesis, by Country USD Billion (2016-2021)
  • Table 21. South America Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 22. South America Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 23. South America Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 24. South America Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 25. Brazil Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 26. Brazil Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 27. Brazil Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 28. Brazil Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 29. Argentina Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 30. Argentina Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 31. Argentina Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 32. Argentina Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 33. Rest of South America Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 34. Rest of South America Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 35. Rest of South America Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 36. Rest of South America Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 37. Asia Pacific Oligonucleiotide Synthesis, by Country USD Billion (2016-2021)
  • Table 38. Asia Pacific Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 39. Asia Pacific Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 40. Asia Pacific Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 41. Asia Pacific Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 42. China Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 43. China Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 44. China Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 45. China Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 46. Japan Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 47. Japan Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 48. Japan Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 49. Japan Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 50. India Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 51. India Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 52. India Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 53. India Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 54. South Korea Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 55. South Korea Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 56. South Korea Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 57. South Korea Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 58. Taiwan Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 59. Taiwan Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 60. Taiwan Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 61. Taiwan Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 62. Australia Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 63. Australia Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 64. Australia Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 65. Australia Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 66. Rest of Asia-Pacific Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 67. Rest of Asia-Pacific Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 68. Rest of Asia-Pacific Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 69. Rest of Asia-Pacific Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 70. Europe Oligonucleiotide Synthesis, by Country USD Billion (2016-2021)
  • Table 71. Europe Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 72. Europe Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 73. Europe Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 74. Europe Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 75. Germany Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 76. Germany Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 77. Germany Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 78. Germany Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 79. France Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 80. France Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 81. France Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 82. France Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 83. Italy Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 84. Italy Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 85. Italy Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 86. Italy Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 87. United Kingdom Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 88. United Kingdom Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 89. United Kingdom Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 90. United Kingdom Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 91. Netherlands Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 92. Netherlands Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 93. Netherlands Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 94. Netherlands Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 95. Rest of Europe Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 96. Rest of Europe Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 97. Rest of Europe Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 98. Rest of Europe Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 99. MEA Oligonucleiotide Synthesis, by Country USD Billion (2016-2021)
  • Table 100. MEA Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 101. MEA Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 102. MEA Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 103. MEA Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 104. Middle East Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 105. Middle East Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 106. Middle East Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 107. Middle East Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 108. Africa Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 109. Africa Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 110. Africa Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 111. Africa Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 112. North America Oligonucleiotide Synthesis, by Country USD Billion (2016-2021)
  • Table 113. North America Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 114. North America Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 115. North America Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 116. North America Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 117. United States Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 118. United States Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 119. United States Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 120. United States Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 121. Canada Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 122. Canada Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 123. Canada Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 124. Canada Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 125. Mexico Oligonucleiotide Synthesis, by Type USD Billion (2016-2021)
  • Table 126. Mexico Oligonucleiotide Synthesis, by Application USD Billion (2016-2021)
  • Table 127. Mexico Oligonucleiotide Synthesis, by End User USD Billion (2016-2021)
  • Table 128. Mexico Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Oligonucleiotide Synthesis: by Type(USD Billion)
  • Table 140. Oligonucleiotide Synthesis Custom Oligonucleotides , by Region USD Billion (2022-2027)
  • Table 141. Oligonucleiotide Synthesis Pre-designed Oligonucleotides , by Region USD Billion (2022-2027)
  • Table 142. Oligonucleiotide Synthesis: by Application(USD Billion)
  • Table 143. Oligonucleiotide Synthesis Research , by Region USD Billion (2022-2027)
  • Table 144. Oligonucleiotide Synthesis Diagnostics , by Region USD Billion (2022-2027)
  • Table 145. Oligonucleiotide Synthesis Therapeutics , by Region USD Billion (2022-2027)
  • Table 146. Oligonucleiotide Synthesis: by End User(USD Billion)
  • Table 147. Oligonucleiotide Synthesis Academic & Research Institutes , by Region USD Billion (2022-2027)
  • Table 148. Oligonucleiotide Synthesis Pharmaceutical & Biotechnology Companies , by Region USD Billion (2022-2027)
  • Table 149. Oligonucleiotide Synthesis Diagnostic Laboratories , by Region USD Billion (2022-2027)
  • Table 150. Oligonucleiotide Synthesis Hospitals , by Region USD Billion (2022-2027)
  • Table 151. Oligonucleiotide Synthesis: by Products made from Oligonucleiotide(USD Billion)
  • Table 152. Oligonucleiotide Synthesis Oligonucleotide-based Drugs , by Region USD Billion (2022-2027)
  • Table 153. Oligonucleiotide Synthesis Primers , by Region USD Billion (2022-2027)
  • Table 154. Oligonucleiotide Synthesis Probes , by Region USD Billion (2022-2027)
  • Table 155. Oligonucleiotide Synthesis Large-scale Synthesized Oligonucleotides , by Region USD Billion (2022-2027)
  • Table 156. Oligonucleiotide Synthesis Intermediate-scale Synthesized Oligonucleotides , by Region USD Billion (2022-2027)
  • Table 157. Oligonucleiotide Synthesis Linkers & Adaptors , by Region USD Billion (2022-2027)
  • Table 158. South America Oligonucleiotide Synthesis, by Country USD Billion (2022-2027)
  • Table 159. South America Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 160. South America Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 161. South America Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 162. South America Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 163. Brazil Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 164. Brazil Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 165. Brazil Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 166. Brazil Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 167. Argentina Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 168. Argentina Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 169. Argentina Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 170. Argentina Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 171. Rest of South America Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 172. Rest of South America Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 173. Rest of South America Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 174. Rest of South America Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 175. Asia Pacific Oligonucleiotide Synthesis, by Country USD Billion (2022-2027)
  • Table 176. Asia Pacific Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 177. Asia Pacific Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 178. Asia Pacific Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 179. Asia Pacific Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 180. China Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 181. China Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 182. China Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 183. China Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 184. Japan Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 185. Japan Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 186. Japan Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 187. Japan Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 188. India Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 189. India Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 190. India Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 191. India Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 192. South Korea Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 193. South Korea Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 194. South Korea Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 195. South Korea Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 196. Taiwan Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 197. Taiwan Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 198. Taiwan Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 199. Taiwan Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 200. Australia Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 201. Australia Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 202. Australia Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 203. Australia Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 204. Rest of Asia-Pacific Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 205. Rest of Asia-Pacific Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 206. Rest of Asia-Pacific Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 207. Rest of Asia-Pacific Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 208. Europe Oligonucleiotide Synthesis, by Country USD Billion (2022-2027)
  • Table 209. Europe Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 210. Europe Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 211. Europe Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 212. Europe Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 213. Germany Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 214. Germany Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 215. Germany Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 216. Germany Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 217. France Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 218. France Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 219. France Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 220. France Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 221. Italy Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 222. Italy Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 223. Italy Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 224. Italy Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 225. United Kingdom Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 226. United Kingdom Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 227. United Kingdom Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 228. United Kingdom Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 229. Netherlands Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 230. Netherlands Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 231. Netherlands Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 232. Netherlands Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 233. Rest of Europe Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 234. Rest of Europe Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 235. Rest of Europe Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 236. Rest of Europe Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 237. MEA Oligonucleiotide Synthesis, by Country USD Billion (2022-2027)
  • Table 238. MEA Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 239. MEA Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 240. MEA Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 241. MEA Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 242. Middle East Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 243. Middle East Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 244. Middle East Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 245. Middle East Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 246. Africa Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 247. Africa Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 248. Africa Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 249. Africa Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 250. North America Oligonucleiotide Synthesis, by Country USD Billion (2022-2027)
  • Table 251. North America Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 252. North America Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 253. North America Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 254. North America Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 255. United States Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 256. United States Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 257. United States Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 258. United States Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 259. Canada Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 260. Canada Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 261. Canada Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 262. Canada Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 263. Mexico Oligonucleiotide Synthesis, by Type USD Billion (2022-2027)
  • Table 264. Mexico Oligonucleiotide Synthesis, by Application USD Billion (2022-2027)
  • Table 265. Mexico Oligonucleiotide Synthesis, by End User USD Billion (2022-2027)
  • Table 266. Mexico Oligonucleiotide Synthesis, by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Oligonucleiotide Synthesis: by Type USD Billion (2016-2021)
  • Figure 5. Global Oligonucleiotide Synthesis: by Application USD Billion (2016-2021)
  • Figure 6. Global Oligonucleiotide Synthesis: by End User USD Billion (2016-2021)
  • Figure 7. Global Oligonucleiotide Synthesis: by Products made from Oligonucleiotide USD Billion (2016-2021)
  • Figure 8. South America Oligonucleiotide Synthesis Share (%), by Country
  • Figure 9. Asia Pacific Oligonucleiotide Synthesis Share (%), by Country
  • Figure 10. Europe Oligonucleiotide Synthesis Share (%), by Country
  • Figure 11. MEA Oligonucleiotide Synthesis Share (%), by Country
  • Figure 12. North America Oligonucleiotide Synthesis Share (%), by Country
  • Figure 13. Global Oligonucleiotide Synthesis share by Players 2021 (%)
  • Figure 14. Global Oligonucleiotide Synthesis share by Players (Top 3) 2021(%)
  • Figure 15. Global Oligonucleiotide Synthesis share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Agilent Technologies, Inc. Revenue, Net Income and Gross profit
  • Figure 18. Agilent Technologies, Inc. Revenue: by Geography 2021
  • Figure 19. ATDBio Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. ATDBio Ltd. (United Kingdom) Revenue: by Geography 2021
  • Figure 21. GE Healthcare Revenue, Net Income and Gross profit
  • Figure 22. GE Healthcare Revenue: by Geography 2021
  • Figure 23. Eurofins Genomics (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Eurofins Genomics (Germany) Revenue: by Geography 2021
  • Figure 25. Eurogentec (Belgium) Revenue, Net Income and Gross profit
  • Figure 26. Eurogentec (Belgium) Revenue: by Geography 2021
  • Figure 27. Bio-Synthesis, Inc. Revenue, Net Income and Gross profit
  • Figure 28. Bio-Synthesis, Inc. Revenue: by Geography 2021
  • Figure 29. BioAutomation Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 30. BioAutomation Corporation (United States) Revenue: by Geography 2021
  • Figure 31. LGC Biosearch Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 32. LGC Biosearch Technologies (United States) Revenue: by Geography 2021
  • Figure 33. Biogen International (United States) Revenue, Net Income and Gross profit
  • Figure 34. Biogen International (United States) Revenue: by Geography 2021
  • Figure 35. Thermo Fisher Scientific, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Thermo Fisher Scientific, Inc. (United States) Revenue: by Geography 2021
  • Figure 37. Global Oligonucleiotide Synthesis: by Type USD Billion (2022-2027)
  • Figure 38. Global Oligonucleiotide Synthesis: by Application USD Billion (2022-2027)
  • Figure 39. Global Oligonucleiotide Synthesis: by End User USD Billion (2022-2027)
  • Figure 40. Global Oligonucleiotide Synthesis: by Products made from Oligonucleiotide USD Billion (2022-2027)
  • Figure 41. South America Oligonucleiotide Synthesis Share (%), by Country
  • Figure 42. Asia Pacific Oligonucleiotide Synthesis Share (%), by Country
  • Figure 43. Europe Oligonucleiotide Synthesis Share (%), by Country
  • Figure 44. MEA Oligonucleiotide Synthesis Share (%), by Country
  • Figure 45. North America Oligonucleiotide Synthesis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Agilent Technologies, Inc.
  • ATDBio Ltd. (United Kingdom)
  • GE Healthcare
  • Eurofins Genomics (Germany)
  • Eurogentec (Belgium)
  • Bio-Synthesis, Inc.
  • BioAutomation Corporation (United States)
  • LGC Biosearch Technologies (United States)
  • Biogen International (United States)
  • Thermo Fisher Scientific, Inc. (United States)
Additional players considered in the study are as follows:
Sarepta Therapeutics , GeneDesign, Inc. (Japan) , GenScript, Inc. , Integrated DNA Technologies (United States) , Nitto Denko Avecia, Inc. , Sarepta Therapeutics (United States)
Select User Access Type

Key Highlights of Report


Jun 2022 125 Pages 71 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Oligonucleiotide Synthesis Market Quantitative research analysis
Global Oligonucleiotide Synthesis Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Oligonucleiotide Synthesis Market is heading robustly to achieve new growth cycle.
The Concentration Rate of Global Oligonucleiotide Synthesis market is dominated by United States Vendors and may generate healthy valuation by 2027.
Companies that are profiled in Global Oligonucleiotide Synthesis Market are Agilent Technologies, Inc., ATDBio Ltd. (United Kingdom), GE Healthcare, Eurofins Genomics (Germany), Eurogentec (Belgium), Bio-Synthesis, Inc., BioAutomation Corporation (United States), LGC Biosearch Technologies (United States), Biogen International (United States) and Thermo Fisher Scientific, Inc. (United States) etc.
  • Increasing Use of Synthesized Oligos in Molecular Diagnostics and Clinical Applications
  • Increasing Government Investments and R&D Expenditure in Pharmaceutical and Biotechnology Companies

Know More About Global Oligonucleiotide Synthesis Market Report?

Have a Query? Click Here

Other Related Reports

Matting Agents Comprehensive Study by Type (Organic, Inorganic), Application (Industrial Coatings, Wood Coatings, Leather Coatings, Architectural Coatings, Others), Form (Powder, Liquid), Grade (Tech...
$ 3350
Polyacrylonitrile Fiber Comprehensive Study by Application (Textile Industry, Medical Field, Packaging Materials, Other) Players and Region - Global Market Outlook to 2024
$ 3500
Industrial Salts Comprehensive Study by Application (Agriculture, Chemical Processing, De-Icing, Oil & Gas, Water Treatment, Others), Source Type (Rock Salt, Natural brine), Production Method (Conven...
$ 3450
Propylene Carbonate Comprehensive Study by Type (Battery grade, High grade, First grade), Application (Solvent, Electrolyte, Chemical Intermediates, Cleaner, Others (Catalyst, Additives), Others), Di...
$ 3650
Putty Powder Comprehensive Study by Type (Interior Wall, Exterior Wall), Vertical (Residential, Commercial), Packaging Type (Packet, Pouch, Bag, Others), Features (No Curing Required, Crack Proof & W...
$ 3800
Potassium Lactate Comprehensive Study by Application (Cosmetics, Food & Beverages, Oil & Gas, Health Care, Fire Protection, Others), Function (Preservatives, Food Additives, Emulsifiers, Bulking Agen...
$ 3650